Longevity, Cancer & Evolution: What Elephants Teach Us About Cancer

Table of Contents

Overview

For decades, cancer research has pursued a single goal: finding a cure. But evolutionary biologist Carlo Maley, director of the Arizona Cancer Evolution Center at Arizona State University, argues for a different approach — managing cancer indefinitely, much as medicine already manages chronic conditions like diabetes or HIV. His ideas, discussed in an interview with the Spanish newspaper El País during a visit to Barcelona, draw on evolutionary biology to explain why cancer resists cures and what nature might teach us about controlling it instead.

Central to Maley's work is Peto's Paradox: large, long-lived animals such as elephants and whales have far more cells than humans, and therefore a theoretically much higher risk of cancer-causing mutations, yet they develop cancer far less often. Studying how these species suppress tumors, Maley suggests, could change how both patients and doctors think about living with the disease.

Myths vs. Clinical Reality

Myth: A successful cancer treatment always means a complete cure

It is a widely held assumption, reinforced by decades of public messaging, that curing cancer outright is the only meaningful measure of medical success. Maley challenges this framing directly.

According to the interview, Maley believes medicine's fixation on a cure has overshadowed a more realistic and, in many cases, more attainable goal: extending life and preserving its quality. He points to how oncology already treats some tumors as manageable, chronic conditions rather than diseases to be eradicated in a single decisive intervention — comparable to how physicians control diabetes or HIV rather than cure them outright. Discussing how modest current benchmarks for treatment success can be, Maley told El País: "A few months… We should be talking about years or decades!"

As specialists in regenerative and precision medicine, we observe that this shift in framing — from cure to durable disease control — reflects a broader trend across chronic disease management, where sustained quality of life is increasingly treated as a primary clinical endpoint in its own right, not a fallback when a cure is unavailable.

Myth: Larger animals with more cells should develop more cancer

Intuitively, an organism with more cells and a longer lifespan should accumulate more DNA-copying errors over time, and therefore face a higher lifetime risk of cancer. This is the logical basis of what scientists call Peto's Paradox — and it is precisely where the intuition breaks down.

Elephants and whales, despite their enormous size and cell counts, have markedly lower cancer rates than humans. Maley's research points to specific evolved mechanisms behind this: elephants carry roughly twenty copies of the p53 gene, one of the body's most important tumor-suppressor genes, which makes them highly sensitive to detecting DNA damage and eliminating affected cells before they can become cancerous. Whales appear to rely on different, still less understood mechanisms, possibly related to more efficient DNA repair.

Natural selection, Maley notes, only reinforces traits that affect survival and reproduction. Because humans historically reproduced and often died from causes other than cancer well before old age, there was less evolutionary pressure to develop the layered cancer-suppression systems seen in elephants and whales.

Myth: The highest possible drug dose is always the most effective cancer strategy

A further assumption worth examining is that maximizing the dose of a cancer drug — killing off as many tumor cells as possible, as quickly as possible — is always the optimal approach. Maley's research into adaptive therapy suggests the opposite may sometimes be true for cancers that cannot realistically be cured.

The underlying logic is ecological: tumor cells compete with one another for oxygen, glucose, and other resources. If a high dose eliminates nearly all drug-sensitive cells, the small population of resistant cells left behind loses its competitors and can expand rapidly and unopposed. A lower, carefully calibrated dose that leaves more sensitive cells in place preserves that competitive pressure, which can slow the emergence of drug resistance.

As specialists in the field, we note that the evidence base for this approach remains preliminary: Maley describes six supporting mouse studies and a single human trial that doubled the time to resistance, with additional clinical trials underway but not yet reporting results. This is an encouraging early signal, not an established standard of care, and the strategy is only under investigation for tumors considered unlikely to be curable through surgery or standard treatment — not for early-stage, localized cancers that remain generally curable through conventional means.

When Should You Consult a Specialist?

The research discussed above is still evolving and should never substitute individualized medical guidance. That said, several general situations warrant a timely evaluation by a board-certified oncologist or genetic counselor:

• Persistent, unexplained symptoms such as significant weight loss, prolonged fatigue, unusual bleeding, or a new lump or mass.

• A personal or family history of cancer, which may warrant genetic counseling or earlier screening.

• An existing cancer diagnosis where treatment goals — cure versus long-term control — have not been clearly discussed with your care team.

• Interest in understanding whether emerging approaches, such as adaptive or dose-modulated therapy, are relevant to your specific diagnosis and whether any clinical trials are currently enrolling.

• Questions about how a chronic-disease management approach might apply to a cancer that is not considered curable by surgery alone.

In all these cases, the right first step is a conversation with a certified specialist — an oncologist, geneticist, or your primary care physician — who can evaluate your specific history and current evidence.

Bottom Line

Maley's research reframes cancer treatment success around a simple idea: evolution has already run countless experiments in tumor suppression in species like elephants and whales, and extending life with quality — not just curing disease — can be a legitimate medical goal in its own right. The findings on adaptive, lower-dose therapy remain preliminary, and any individual treatment decisions should be made in conversation with a qualified specialist.

This article is based on an interview with Carlo Maley conducted by El País (english.elpais.com), published July 28, 2026, in which Maley discusses his evolutionary biology research on cancer suppression in large, long-lived animals and its implications for how cancer is treated and managed in humans. Co-authored by Dr. Aleksandr Orlov and Carlos López (CEO), Precision Bioclinic.